Silver Book Fact

If the progression of Parkinson’s disease were slowed by 50%, there would be a 35% reduction in excess costs.

Johnson S, Diener M, Kaltenboeck A, Binbaum H, et al. An Economic Model of Parkinson’s Disease: Implications for slowing progression in the United States. Mov Disord. 2013; 28(3). http://www.ncbi.nlm.nih.gov/pubmed/23404374

Reference

Title
An Economic Model of Parkinson’s Disease: Implications for slowing progression in the United States
Publication
Mov Disord
Publication Date
2013
Authors
Johnson S, Diener M, Kaltenboeck A, Binbaum H, et al.
Volume & Issue
Volume 28, Issue 3
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • A clinical trial in Europe found that treating Alzheimer’s patients with an Alzheimer’s drug reduced annual treatment costs by $1,000 per patient.  
  • Impact of Slowed Progression on Alzheimer’s Disease Growth, Americans Age 65 and Older with Alzheimer’s, 2010-2050  
  • According to the Pharmaceutical Research and Manufacturers of America, because of medical research, the number of Americans with Alzheimer’s could decrease by 3 million in 2025.  
  • Valuing a QALY at $175,000, new drugs that would produce a 5-year delay in Alzheimer’s disease onset for all new cases between 2010 and 2050 would yield a benefit of…  
  • Medicaid Costs, 5-Year Delayed Onset